Our studies suggest low levels of IRF2 may be responsible for some of the poor immunogenicity of many tumors and that in preclinical studies, type I or II interferons can induce tumor expression of IRF2, enhancing MHC I expression and lead to better rejection, including in combination with CPI treatment. This evidence concerns the gene SGCG and neoplasm.